Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

Elisabeth Hjardem, Mikkel Østergaard, Jan Pødenphant, Ulrik Tarp, Lis Smedegaard Andersen, Jette Bing, Elisabeth Peen, Hanne Merete Lindegaard, Vibeke Stevenius Ringsdal, Anne Rødgaard, Jens Skøt, Annette Hansen, Hans Henrik Mogensen, Janne Unkerskov, Merete Hetland, Merete Lund Hetland